BGG supports the safety and efficacy of its CO2 Saw Palmetto Extract

Wednesday, September 25, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Two human clinical trials validate the efficacy and safety of BGG's Saw Palmetto Extract

FORT COLLINS, Colo., Sept. 25, 2019 /PRNewswire-PRWeb/ -- BGG has successfully completed and published two clinical trials

on its Saw Palmetto extract to support its safety and reconfirm its efficacy. One of the clinical trials was conducted on 44 volunteers who were given BGG's Saw Palmetto extract or placebo over an eight-week period. The treatment group experienced a statistically significant reduction in urinary issues versus placebo (Kushima et al., 2018). The second clinical trial established safety at 6X the recommended dosage (Sekikawa et al., 2019).

"We are extremely pleased to offer a Saw Palmetto extract that has been proven efficacious and safe through peer-reviewed human research," said Yanmei Li, PhD, BGG's Chief Scientific Officer. "BGG prides itself not only on producing products with industry-leading quality, but also on sponsoring clinical research to validate our products' ability to positively affect consumers' health. This combination of top quality and clinical validation has been extremely well-received by leading brands in the market for our other products, and we look forward to similar success in the Saw Palmetto category."

BGG's Global Chief Marketing Officer and CEO of BGG Europe Christian Artaria observed, "The Saw Palmetto market has been in turmoil recently due to a series of poor harvests, which have added additional costs to an already costly manual harvesting. As a consequence, adulteration with inexpensive food-based oils or with blends of lipids that mimic the phytochemical profile of a genuine Serenoa extract has been rampant. At BGG we offer to the market genuine, safe and clinically-supported products, and the new studies performed on our CO2 Saw Palmetto extract come at the perfect time."

Sekikawa, T. Kizawa, Y. Li, Y. Miura, N. (2019). "A clinical study for evaluating the safety of excessive consumption of saw palmetto extract." Japanese Pharmacology and Therapeutics. 47. 445-452. Kushima, M. Okamoto, K. Kizawa, Y. Sekikawa, T. Li, Y. Takara, T. (2018) "A Verification Study on the Improvement of Urination Issues with Ingestion of Saw Palmetto Fruit Extract: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study." Pharmacometrics 95(5/6): 101-111, 2018.

About BGG BGG is a global B2B supplier of ingredients sourced from nature that improve consumer wellness. Building on 25 years of innovative leadership, BGG provides consumer product makers with efficacious ingredients of outstanding quality. This is achieved by specialized sourcing, cultivation and production in the best global regions. BGG's extensive portfolio originates from algae, fruits and plants. BGG employs a staff of approximately 400, has 6 production sites, international branches in North America, Japan, China and Switzerland and manages sales in more over 100 countries. BGG is ISO9001, ISO22000 and GMP certified.

Further Information on BGG: http://www.bggworld.com Press Contact: Christian Artaria, Global Chief Marketing Officer

 

SOURCE BGG



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store